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ABSTRACT
Organometals induce platelet aggregation and inorganic metal ions such as Cd2+ or Pb2+ sensitise
human blood platelets to aggregating agents and this action is associated with the liberation of arachidonic
acid and eicosanoid formation. The same mechanism is obseed using human leukaemia cells (I-60)
when treated with MeHgCI or Et3PbCI. The fatty acid liberation within human platelets and HL-60 cells
could only be inhibited with phospholipaseA2 inhibitors of different specificity.
Preincubation of the cells with pertussis toxin reduces the activation induced by Et3PbCI to a great
extent. The non-catalytic B subunit, that only mediates the binding of the toxin to the cell membranes, has
no effect at all. When summarised, these results suggest that one possible mechanism for the stimulation of
phospholipase A2 by Et3PbC1 functions via a G-protein dependent pathway.
INTRODUCTION
The cascade of arachidonic acid liberation and its metabolisation becomes more and more hnportant
within physiological and pathological processes. With regard to immunological and inflammatory reactions
there are some hints for the involvement of xenobiotics in these mechanisms.L2 Cd2+ ions sensitise human
blood platelets to aggregating agents3 and the organometallic compounds methylmercury (MeHgC1),
triethyllead (Et3PbCI) and triethyltin induce platelet aggregation.4"6 This activation of platelets is
associated with the liberation of arachidonic acid and eicosanoid formation. As these metals accumulate in
the environment7 and the biospheres the effects of these compounds and their ability to increase lipid
mediators of inflammatory reactions are of great interest. The possible induction of the cellular lipid
metabolism by xenobiotics and the following increase of available precursors of lipid mediators could
possibly lead to immunotoxic effects.
These experiments gave a greater insight into the mechanism by which the lipid metabolism is
affected. The results shown here corroborate the assumption that the activation of phospholipase A2 is at
least partly triggered via a G-protein.
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MATERIALS & METHODS
Chemicals Quinacrine and p-bromophenacylbromide (pBPB) were obtained from Serva
(Heidelberg). The calcium ionophore A 23187, pertussis toxin and fMet-Leu-Phe (fMLP) were from Sigma
(Munich), the pertussis toxinB subunit was from List Biological Laboratories (Campbell, USA) and the
SIL G Polygram thin-layer plates were from Macherey & Nagel (DOren). The [l-14C]-arachidonic acid
(2.07 GBq/mmol) and [3H]-arachidonic acid (3.66TBq/mmol) were purchased from Amersham
(Braunschweig). All other chemicals were of analytical grade and solvents for HPLC were obtained from
Promochem (Wesel).
Platelet-rich plasma and determination ofaggregation Fresh human blood from healthy
donors (3.8% citrate/blood, 1:9, v/v) was centrifuged at 340 g for 10 min at 22C to get platelet-rich plasma
(PRP). Donors must have abstained from all drugs for more than 2 weeks. Platelet-poor plasma was
prepared by further centrifugation of the remaining blood at 5 000g for 15 rain at 4C. After counting the
platelets in PRP their number was adjusted with autologous platelet-poor plasma to 300 000/pl. PRP was
added to each cuvette, stirred at 1 000 rpm at 37C and the light transmission during aggregation was
monitored by use of an Elvi aggregometer. Heavy metal compounds were added as aqueous or ethanolic
solution to give the concentrations indicated.
Preparation of[HJ-arachidonic acid labelledplatelets PRP was incubated with [3H]-arachi-
donic acid (37 kBq/ml) for 2 h at 35C under constant stirring. The labelled platelets were washed twice
with 5 ml of a modified Tyrode buffer5 and experiments were started 45 min after final resuspension.
Incubation ofilL-60 cells HL-60 cells were grown in suspension culture in RPMI 1640 medium
supplemented with 15% foetal calf sennn. They were induced to differentiate to mature granulocytes by
the addition of 1.3% dimethyl sulphoxide for 5 days. The cells were harvested by centtifugation, washed
once with RPMI without any additives and f’mally resuspended in medium containing 1% dimethyl
sulphoxide and 3.3% foetal calf serum at a concentration of 1 107 cells/ml. Experiments were started
after 30min standing. The cell suspensions (3 ml) were then incubated at 37C with 10ttM
calcium ionophore A23187 or Et3PbCI as indicated. In the case of radioactive prelabelling,
[t4C]-arachidonic acid was dissolved in dimethyl sulphoxide, added at day 4 (92.5 kBq/50 ml) to the
culture medium and the cells were incubated overnight. The labelled cells were washed twice with RPMI
and resuspended as described above.
Lipid extraction and separation oflipid classes After incubation of the cell suspensions the
lipids were extracted as reported earlier.9 The extract was dried under nitrogen, taken up in chloroform,
applied to bonded phase aminopropyl columns (Waters) and separated into a phospholipid-, free fatty acid-
and triacylglyceml-fraction. After hydrolysis of the triacylglycerols and the phospholipids, the fatty acids
were estered withpBPB. The phenacyl esters ofthe fatty acids were then analysed using HPLC.
Radioactive lipids were extracted as described above. The dried lipids were taken up in CHCI3 and
spotted onto SIL G polyester plates (20 cm 20 cm) and separated by thin-layer chromatography as
described elsewhere.9 The Rf-values for the lipid classes were determined by comparison of their migration
with that of commercial standards. This system gives good separation of all cellular lipids.
HPLC analysis The experimental equipment consisted of two HPLC pumps (Waters, model
510), an automated sample processor (Waters, WISP), a programmable multiwavelength detector (Waters,
model 490), and the chromatograms were evaluated with a Waters Maxima 820 chromatography data
station. The analysis was carried out as reported earlier. 12 The fatty acid esters were detected at 254 nm
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TABLE 1:
and the recovery from the whole procedure (extraction, separation, hydrolysis and derivatisation) was
estimated by the addition ofthe internal standard margaric acid.
Stimulation of human platelet aggregation by various heavy metal compounds.
Pretreatment
50 pM HgCI2
50 pM HgCI2
50 IJM CdO
50 pM CdO
50 pM CdCI2
50 IJM CdCI2
50 pM PbCI2
50 pM PbCI2
100 pM Et3PbCI
40 pM MeHgCI
CdCI2+PbCI2+Et3PbCI
(each 20 HM)
Treatment(R)
collagen
arachidonic acid
collagen
arachidonic acid
collagen
arachidonic acid
collagen
arachidonic acid
collagen
amchidonic acid
% Aggregation
40
60
60
70
90
90
90
Heavy metal compounds were added to PRP to give the final concentrations as indicated. CdO was dispersed
by soniflcation in buffer. After a preincubation pedod of 5 rain, collagen or arachidonic acid were added in
sub-threshold concentrations and aggregation was measured using an Elvi aggregometer and constant stirdng
for a further 15 rain. Values of aggregation are given in % of light transmission as compared to stimulation with
optimal concentrations of collagen or arachidonic acid, respectively.
(R): sub-threshold concentrations of collagen (0.32 pg/ml) or amchidonic acid (0.26 mM) that were not able to
induce platelet aggregation by themselves.
RESULTS
Platelet aggregation studies Human blood platelets can be stimulated in vitro with exogenous
arachidonic acid or collagen to aggregate. However, low concentrations of these agents, 0.26mM
arachidonic acid or 0.32 pg/ml collagen, were not sufficient to stimulate platelets. On the other hand,
inorganic metal ions as Pb2+ or Cd2+ showed synergistic action in activation of blood platelets together
with these low concentrations of physiological inducers (Tab. 1). Although other inorganic compounds like
Hg2+ or CdO failed to induce platelet aggregation, in solution or suspension of small particles,
respectively, the organic heavy metal compounds Et3PbCI and MeHgCI were able to stimulate this reaction
without the addition of any physiological agent (Tab. 1).
Inhibitors ofplateletfunctions andphospholipase A2 Previous reports have shown that
human platelets, as well as HL-60 cells, liberate arachidonic acid from phospholipids and metabolise it to
eicosanoids following incubation with the organometallic compounds. 5,9 Compared to the controls with or
without thrombin, Et3PbCI and MeHgCI induced the liberation and metabolisation of arachidonic acid to a
stupendous extent (Tab. 2). To elucidate which step(s) in the reaction cascade is(are) affected,
[3H]-arachidonic acid labelled platelets were incubated with different compounds capable of affecting
enzyme or metabolic reactions. Forskolin, a potent stimulator of adenylate cyclase, inhibits platelet
aggregation by raising the intracellular level of cyclic AMP. Pretreatment of platelets with forskolin and
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subsequent incubation with either Et3PbCI or MeHgCI, however, could not prevent liberation of
arachidonic acid and its metabolisation (Tab. 2) in spite of total inhibition ofplatelet aggregation.
The action of acetylsalicylic acid (ASA) was tested; ASA is a known inhibitor of cyclooxygenase.
Even in this case only the aggregation was prevented because the formation of the cyclooxygenase
products thromboxane B2 and 12-hydroxy-5,8,10-heptadecatrienoic acid was drastically reduced, whereas
the lipoxygenase product 12-hydroxy-5,8,10,14-eicosatetraenoic acid was increased (Tab. 2). Only the third
compound, quinacrine, was able to inhibit both aggregation and arachidonic acid liberation induced by the
heavy metal compounds (Tab. 2).
TABLE 2: Effect of metabolic inhibitors on heavy metal induced lipid metabolism.
Treatment Human Platelets Cyclooxygenase Lipoxygenase Product
untreated
Thrombin (1 U/ml)
75 pM Et3PbCI
75 pM Et3PbCI + forskolin
75 pM Et3PbCI + ASA
75 pM Et3PbCI + quinacrine
50 pM MeHgCI
50 pM MeHgCI + forskolin
50 pM MeHgCI + ASA
50 pM MeHgCI + quinacrine
cpm
270
5.180
17.578
18.093
2.057
1.010
+148
+510
+1.683
+2.418
+529
+436
23.438
24.380
4.095
548
+1.656
+873
+1.737
+232
cpm
105 +68
1.140 +330
15.200 +1.410
12.380 +1.610
23.310 +1.150
730 +180
5.860 +319
7.437 +400
26.020 +3.892
195 +113
Treatment HL-60 Cells
untreated
fMLP (10 pa)
100 pM Et3PbCI
100 pM Et3PbCI + quinacrine
100 HM Et3PbCI + pBPB
free Arachidonic Acid
cpm
1.570
12.383
+461
+1.364
20.539 +3.703
1.024 +686
1.719 +205
’Prelabelled platelets wer preincubated’with 100 IJM forsk01in (15 min), mM acetylsalicylic acid (ASA, 15 min)
or mM quinacrine (5 rain) and prelabelled HL-60 cells were preincubated with mM quinacrine (5 min) or
50 pM pBPB (30 rain) before thrombin, fMLP, Et3PbCI or MeHgCI were added and the incubation was
continued for 15 min (platelets) or 30 rain (HL-60). Lipids were extracted and separated by t.l.c. Values are the
mean of three to five experiments _+s.e.m.
Cyciooxygenase products: sum of label within thromboxane B2 and 12-hydroxy-5,8,10-heptadecatrienoic acid;
lipoxygenase product: radioactivity within 12-hydroxy-5,8,10,14-eicosatetraenoic acid.
The amount of free, unmetabolised arachidonic acid within platelets was negligible, whereas in HL-60 cells it
was the main portion.
Furthermore, HL-60 cells, differentiated with dimethyl sulphoxide to mature granulocytes, were
incubated for 24 h in the presence of [t4C]-arachidonic acid. As shown for human blood platelets, the
liberation of arachidonic acid is well inducible by Et3PbCI and could be totally inhibited in these cells by
the inhibitors of phospholipase A2, quinacrine andpBPB (Tab. 2).
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Fatty acid liberation and lipid remodelling in HL-60 cells In another set of experiments
without prelabelling of the cells, the fatty acid composition of the cellular lipids were charactedsed by
HPLC. When HL-60 cells were treated with lower concentrations of the xenobiotic for longer periods of
time, a loss of fatty acids within the phospholipids was obvious, although no free arachidonic acid could be
detected. All liberated fatty acids were re-esteritied continuously back into the phospholipids or
triacylglycerols. The re-incorporation into triacylglycerols reveals information on nearly all of the fatty
acids present in the cell. Above all, the non-cytotoxic concentration of Et3PbCI (0.5 txM) induced a
substantial transfer from cellular phospholipids to triacylglycerols not only of arachidonic acid but also of
linoleic, oleic and palmitic acid as shown in Fig. 1.
1,0
0,5
Et3Pb
+
Control
5 10 15 20 25
Time [min]
Figure 1: Shift of fatty acids into triacylglycerol fraction of HL-60 cells induced by low concentrations of Et3PbCI.
Differentiated HL-60 cells were treated for 24 h with
vehicle only (control; or with 0.5 pM Et3PbCI
Lipids were extracted and separated using bonded phase columns into a phospholipid-, free fatty acid- and
tdacylglyceml-fraction. After hydrolysis of the phospholipid- and triacylglycerol-fractions, the fatty acid phenacyl esters
were prepared and submitted to HPLC analysis. Ordinate: absorbance units full scale (AUFS) at 254 nm; abscissa: time
(min).
C16:0 palmilic acid; C18:0 stearic acid; C18:1 oleic add; C18:2 linoleic acid; C20:3 eicosatrienoic acid;
C20:4 arachidonic acid; C17:0 internal standard margadc add.
Effects of pertussis toxin and its B-oligomer on Et3PbCI stimulated fiberation of
arachidonic acid [14C]-arachidonic acid prelabelled HL-60 cells were incubated for 3 h at
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37C with 1 000 ng/ml pertussis toxin or an equivalent amount of its B-oligomer. During this period of
time no alteration of incorporation and distribution of [4C]-arachidonic acid within the lipid classes could
be detectexl (clam not shown). Fig. 2 shows that Et3PbCl-stimulation is higly sensitive to pertussis toxin.
Whereas the radioactivity within the neutral lipids is absolutely identical within the three samples, the
arachidonic acid spot of the pertussis toxin treated cells contains only 35% of arachidonic acid as compar
with B-oligomer or not pretreated cells.
DISCUSSION
The quantity of free unsaturated fatty acids within human blood platelets and HL-60 cells is very
low3 but these cell types respond to exogenous stimuli, e.g. thrombin, collagen, A 23187, or fMLP, with a
rapid increase above all of free arachidonic acid. This is an important metabolic pathway and thus, these
cells are provided with an efficient regulatory mechanism in controlling free fatty acid concentration.
Involved in these processes are the fatty acid liberating enzymes, phospholipaseC and
diacylglycerol lipase or phospholipase A, and the reacylating enzymes, arachidonoyl=CoA synthetase,
lysophospholipid acyltransferase and diacylglycerol acyltransferase.4
+B-Oligomer
Figure 2: Effect of pertussis toxin and its
B-oligomer on Et3PbCI-induced arachidonic aLs acid liberation in HL-60 cells.
[14C]_arachidonic acid prelabelled and
differentiated HL-60 cells were preincubated
for 3 h with 000 ng/ml pertussis toxin (PT) or
an equivalent amount of its B-oligomer before
the cells were stimulated with 50 HM Et3PbCI
(20 min). Lipids were extracted and separated
by t.l.c.
Shown is an autoradiography of that part of the
OIM Et3Pb
+ t.l.c, plate containing the spots of the free
arachidonic acid (fAA) and the neutral lipids
(NLs).
fAA
+PT
+ + +
In various cell types, the thiol-blocking activity of heavy metals leads to an inhibition of the
reacylation of frcc fatty acids into phospholipids. ]5,16 Et3PbCl inhibits the incorporation of exogenously
added [14C]-arachidonic acid into cellular lipids9 as MeHgC115, but at low concentrations (< 1 gl no
inhibition of [14C]-arachidonic acid incorporation could be observed.9 However, the liberation and
subsequent redistribution of fatty acids still occurs at these low concentrations (Fig. 1).
As shown by the use of various inhibitors it could be demonstrated that the heavy metal induced
effects are dependent on fatty acid liberation from phospholipids. Inhibitors of phospholipasc A2, such as
quinacrine or pBPB7, could prevent this reaction in both cell types, human blood platelets and HL-60
cells, indicating a central role of this enzyme. In order to detect whether a direct stimulation of
phospholipase A2 by organic lead compounds occurs or any preceding components in the signal
transduction mechanism is affected by Et3PbC1, the pertussis toxin sensitivity of this mechanism was
tested. These experiments clearly show that only the holotoxin and not its membrane binding subunit, the
B-oligomcr, is responsible for nearly 70% reduction of the metal-effect. It becomes more and more evident
that phospholipase A2 is coupled to membrane receptors via G-proteins18 and these results point to a
G-protein dependent mechanism for the stimulation ofphospholipase A2 by the heavy metals.
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Phospholipases are important enzymes within regulatory processes inducible by external signals.
Their products are second messengers with a multitude of functions, intra- as well as intercellular.
Especially neutmphilic granulocytes are able to interact with various cell types, such as macrophages, mast
cells, platelets, polymorphonuclear leukocytes and many others, e.g. via their products of the
phospholipase A2 cascade.9. All three phospholipases shown in Fig. 3 can be affected by various
stimulators from outside the cell2-22 and may affect each other. The substances produced as the result of
phospholipase A2 activity, i.e. the eicosanoids and the platelet activating factor, have been studied as
potent mediators of immunological reactions. 19,23,24 The enhanced production ofPAF as well as the rise in
intracellular calcium concentration could be demonstrated in our laboratory.2,2
The concentrations of organic lead used in the experiments come close to those in normal human
brains as reported by Nielsen et al. (1978). They have found organic lead in quantifies up to
50 ng Pb/g wet weight and the lowest amount used to stimulate HL-60 cells was 70 ng Pb/ml. Such low
concentrations of lead compounds are able to induce enzyme activities as shown here or reported
elsewhere.27
/ PAFI
E,C, +
Figure 3: Scheme showing the role of phospholipases in second messenger formation.
Stimulation of Phospholipase A2 (PLA2) by heavy metal compounds (G)) leads to potent cell stimulators such as free
arachidonic acid (fAA) and subsequently to the eicosanoicls (pmstaglandins, leukotrienes, thmmboxanes) and/or via the
lysophospholipids (IPL) to the platelet-actJvating factor (PAF). These cellular signalling mediators induce other
phospholipases via membrane receptors such as phospholipase C (PLC) or phospholipase D (PLD). PLD mainly
hydmlyses phosphatidylcholine to give phosphatidic add (PA). PLC hydrolysis of phosphatidylinositolbisphosphate
yields diacylglyceml (DG) and inositol triphosphate (IP3). Whereas DG stimulates protein kinase C (PKC), the IP3
regulates intmcellular calcium concentration. 1T = increased parameters after heavy metal treatment.
A large number of hnportant cellular processes, such as lipid mediator release or membrane
functions, are dependent on signal transduction mechanisms that could be induced by physiological agents.
On the other hand, more .and more evidence arises that xenobiotics, e.g. heavy metal compounds, may be
involved in immunological reactions or in hypersensitisation of organisms to natural products2,2s by
lowering the threshold of cellular sensibility possibly via inducing the phospholipase A2 to a higher level of
basal activity.
ACKNOWLEDGMENTS
I am grateful to Helga Steegbom for superb technical assistance and Lindsay Yule for reviewing the
manuscript before its submission.
97Vol. 2, No. 2, 1995
REFERENCES
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
22.
23.
24.
25.
26.
Stimulation ofPhospholipaseA2 by ToxicMain Group Heavy Metals:
PartlyMediated by G-Proteins?
S. Takafuchi, S. Suztdd, K. Koizumi, K. Tadokoro, T. Miyamoto, R. Ikemofi and M. Muranaka,
J. Allergy Clin. Immunol. 79 (1987) 639-645.
P. Pietsch, H.W. Vohr, K. Degitz and E. Gleichmann, lnt. Arch. Allergy Appl. Immunol. 90 (1989)
47-53.
L. Caprino, G. Togna, and A.R. Togna, Pharmacol. Res. Commun. 11 (1979) 731-737.
D.E. Macfarlane, Mol. Pharmacol. 19 (1981) 470-476.
H.F. Krug and J. Bemdt, Eur. J. Biochem. 162 (1987) 293-298.
J.R. O’Brien, Thromb. Diath. Haemorrh. 9 (1963) 330-334.
J.O. Nriagu and J.M. Pacyna, Nature (Lond.) 333 (1988) 134-139.
T. Nielsen, K.A. Jensen, and P. Grandjean, Nature (Lond.) 274 (1978) 602-603.
H.F. Krug, and H. Culig, Mol. Pharmacol. 39 (1991) 511-516.
M.A. Kaluzny, L.A. Duncan, M.V. Merritt and D.E. Epps, J. LipidRes. 26 (1985) 135-140.
H.D. Durst, M. Milano, E.J. Kiktajr, S.A. Connelly and E. Grushka, Anal. Chem. 47 (1975)
1797-1801.
M. Piittrnann, H.F. Krug, E. yon Ochsenstein and R. Kattermann, Clin. Chem. 39 (1993) 825-832.
T.K. Bills, J.B. Smith and M.J. Silver, J. Clin. lnvest. 60 (1977) 1-6.
R.F. Irvine, Biochem. J. 204 (1982) 3-16.
W. Hornberger and H. Patscheke, Eur. J. Biochem. 187 (1990) 175-181.
S.A. Hunter, S. Burstein and C. Sedor, Biochim. Biophys. Acta 793 (1984) 202-212.
A. Erman, R. Azud and A. Raz, Biochem. Pharmacol. 32 (1983) 2083-2087.
S. Cockcroft, C.P. Nielson and J. Stutchfield, Biochem. Soc. Transact. 19 (1991) 333-336.
W. KOnig, W. SchOnfeld, M. Raulf, M. KOller, J. KnOller, J. Scheffer and J. Brom, Eicosanoids 3
(1990) 1-22.
M.J. Berridge, Nature (Lond.) 361 (1993) 315-325.
M.M. Billah, J.K. Pai, T.J. Mullmann, R.W. Egan and M.I. Siegel, J. Biol. Chem. ]64 (1989)
9069-906.
J. Chang, J.H. Musser and H. MGregor, Biochem. Pharmacol. 36 (1987) 2429-2436.
B.M. Czametzki, A. MOller, J. Grabbe and T. Rosenbach, Allergologie 13 (1990) 411-414.
P.J. Barnes, K.F. Chung and C.P. Page, J. Allergy Clin. Immunol. $1 (1988) 919-934.
H.F. Krug, D. Mattem, J. Bidault and E. Ninio, Environm. Health Persp. 10] (1994) 331-334.
H.F. Krug, A. Kger and H., Dieterieh, In: Frontiers oforganogermanium, -tin and-lead chemistry,
E. Lukevics and L. Igaatovieh (eds), Latvian Institute ofOrgani Synthesis, Riga (1993) 273-281.
J. Markova and G.W. Goldstein, Nature (Lond.) 334 (1988) 71-73.
D. Beyersmann, S. Hehtenberg, C. Block and H. Kirchherr, In: Metal compounds in environment
and life. Interrelation between chemistry and biology, E. Merian and W. Haerdi (eds), SCience and
Technology Letters, Northwood (1992) 187-192.
Received" November 3, 1994 Accepted" November 16, 1994 Received in
revised camera-ready format: December 7, 1994
98